In addition, DDB2 reduces motility and invasiveness of breast cancer cells and represses epithelial-to-mesenchymal transition (EMT) in colon cancer (14) and in oral/head and neck squamous cell carcinoma (HNSCC) (15). Here, DDB2 is linked to colonic neoplasm.